1. Home
  2. IMRN vs SONM Comparison

IMRN vs SONM Comparison

Compare IMRN & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • SONM
  • Stock Information
  • Founded
  • IMRN 1994
  • SONM 1999
  • Country
  • IMRN Australia
  • SONM United States
  • Employees
  • IMRN N/A
  • SONM N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • SONM Telecommunications Equipment
  • Sector
  • IMRN Health Care
  • SONM Telecommunications
  • Exchange
  • IMRN Nasdaq
  • SONM Nasdaq
  • Market Cap
  • IMRN 9.2M
  • SONM 10.2M
  • IPO Year
  • IMRN N/A
  • SONM 2019
  • Fundamental
  • Price
  • IMRN $1.88
  • SONM $1.49
  • Analyst Decision
  • IMRN Strong Buy
  • SONM
  • Analyst Count
  • IMRN 1
  • SONM 0
  • Target Price
  • IMRN $5.00
  • SONM N/A
  • AVG Volume (30 Days)
  • IMRN 25.2K
  • SONM 11.6M
  • Earning Date
  • IMRN 07-07-2025
  • SONM 08-08-2025
  • Dividend Yield
  • IMRN N/A
  • SONM N/A
  • EPS Growth
  • IMRN N/A
  • SONM N/A
  • EPS
  • IMRN N/A
  • SONM N/A
  • Revenue
  • IMRN $4,048,286.00
  • SONM $58,243,000.00
  • Revenue This Year
  • IMRN N/A
  • SONM $127.68
  • Revenue Next Year
  • IMRN N/A
  • SONM N/A
  • P/E Ratio
  • IMRN N/A
  • SONM N/A
  • Revenue Growth
  • IMRN 82.90
  • SONM N/A
  • 52 Week Low
  • IMRN $1.50
  • SONM $0.85
  • 52 Week High
  • IMRN $2.87
  • SONM $10.50
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 58.70
  • SONM 59.58
  • Support Level
  • IMRN $1.68
  • SONM $0.97
  • Resistance Level
  • IMRN $1.94
  • SONM $2.08
  • Average True Range (ATR)
  • IMRN 0.09
  • SONM 0.30
  • MACD
  • IMRN 0.02
  • SONM 0.06
  • Stochastic Oscillator
  • IMRN 76.92
  • SONM 58.23

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: